Immunohistochemical analysis showed that STARD4 knockdown or lenvatinib either decreased the protein expression of p-EGFR, p-PI3K, and p-AKT in the tumor tissues, while the combination of STARD4 knockdown with lenvatinib exerted a significant synergistic inhibitory effect on the phosphorylation of EGFR, PI3K, and AKT (Fig. 8E). Here, STARD4 is linked to neoplasm.